The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
For decades, cytotoxic therapy was considered ineffective for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Earlier therapies such as estramustine and mitoxantrone received regulatory approval based upon improvement in palliative endpoints. In 2004, docetaxel became the f...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2014-06-01
|
Series: | Therapeutic Advances in Urology |
Online Access: | https://doi.org/10.1177/1756287214528557 |
id |
doaj-ebac16219e494239830352945a0192d3 |
---|---|
record_format |
Article |
spelling |
doaj-ebac16219e494239830352945a0192d32020-11-25T02:50:10ZengSAGE PublishingTherapeutic Advances in Urology1756-28721756-28802014-06-01610.1177/1756287214528557The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancerChe-Kai TsaoElena CuttingJacob MartinWilliam K. OhFor decades, cytotoxic therapy was considered ineffective for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Earlier therapies such as estramustine and mitoxantrone received regulatory approval based upon improvement in palliative endpoints. In 2004, docetaxel became the first treatment to demonstrate a significant survival benefit in patients with mCRPC based on two randomized phase III studies, TAX327 and SWOG 99-16. Cabazitaxel, a third-generation taxane, was chosen for clinical development based on its decreased affinity for the drug efflux pump, p-glycoprotein, which is a frequent cause of drug resistance in docetaxel-resistant preclinical models. In 2010, cabazitaxel was approved by the US Food and Drug Administration as the first therapy to show a survival benefit for the treatment of patients with docetaxel-refractory mCRPC. This review summarizes the existing literature on the use of cabazitaxel, focusing on its efficacy and safety in combination with prednisone in the treatment of mCRPC, as well as its role in an era of new therapeutic options.https://doi.org/10.1177/1756287214528557 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Che-Kai Tsao Elena Cutting Jacob Martin William K. Oh |
spellingShingle |
Che-Kai Tsao Elena Cutting Jacob Martin William K. Oh The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer Therapeutic Advances in Urology |
author_facet |
Che-Kai Tsao Elena Cutting Jacob Martin William K. Oh |
author_sort |
Che-Kai Tsao |
title |
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer |
title_short |
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer |
title_full |
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer |
title_fullStr |
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer |
title_full_unstemmed |
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer |
title_sort |
role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Urology |
issn |
1756-2872 1756-2880 |
publishDate |
2014-06-01 |
description |
For decades, cytotoxic therapy was considered ineffective for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Earlier therapies such as estramustine and mitoxantrone received regulatory approval based upon improvement in palliative endpoints. In 2004, docetaxel became the first treatment to demonstrate a significant survival benefit in patients with mCRPC based on two randomized phase III studies, TAX327 and SWOG 99-16. Cabazitaxel, a third-generation taxane, was chosen for clinical development based on its decreased affinity for the drug efflux pump, p-glycoprotein, which is a frequent cause of drug resistance in docetaxel-resistant preclinical models. In 2010, cabazitaxel was approved by the US Food and Drug Administration as the first therapy to show a survival benefit for the treatment of patients with docetaxel-refractory mCRPC. This review summarizes the existing literature on the use of cabazitaxel, focusing on its efficacy and safety in combination with prednisone in the treatment of mCRPC, as well as its role in an era of new therapeutic options. |
url |
https://doi.org/10.1177/1756287214528557 |
work_keys_str_mv |
AT chekaitsao theroleofcabazitaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT elenacutting theroleofcabazitaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT jacobmartin theroleofcabazitaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT williamkoh theroleofcabazitaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT chekaitsao roleofcabazitaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT elenacutting roleofcabazitaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT jacobmartin roleofcabazitaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT williamkoh roleofcabazitaxelinthetreatmentofmetastaticcastrationresistantprostatecancer |
_version_ |
1724739524330782720 |